Shopping Cart
Remove All
Your shopping cart is currently empty
EGFR/HER2-IN-18 is a stable dual inhibitor targeting EGFR and HER2, with IC50 values of 0.09 μM and 0.08 μM, respectively. It exhibits broad-spectrum anticancer activity and can induce apoptosis and inhibit the cell cycle in MCF-7 cells. EGFR/HER2-IN-18 is applicable for breast cancer research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | EGFR/HER2-IN-18 is a stable dual inhibitor targeting EGFR and HER2, with IC50 values of 0.09 μM and 0.08 μM, respectively. It exhibits broad-spectrum anticancer activity and can induce apoptosis and inhibit the cell cycle in MCF-7 cells. EGFR/HER2-IN-18 is applicable for breast cancer research. |
| In vitro | EGFR/HER2-IN-18 (Compound 10f) exhibits significant cytotoxicity with IC 50 values of 3.90 μM in HePG-2, 7.35 μM in HCT-116, and 2.84 μM in MCF-7 cancer cell lines over 24 hours. It demonstrates strong cytotoxic effects against resistant cell lines: 6.971 μM in SKBr3 (compared to Lapatinib IC 50 of 9.614 μM), 2.769 μM in BT474 (Lapatinib IC 50 of 23.691 μM), and 11.472 μM in MDA-MB-453 (Lapatinib IC 50 of 29.762 μM). Additionally, EGFR/HER2-IN-18 at 39.8 μg/ml for 48 hours induces apoptosis in MCF-7 cells. It also causes G0/G1 phase cell cycle arrest in MCF-7 cells (77%) after 48 hours, compared to 70% in the control group. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.